Phreesia, Inc. (NYSE:PHR) Short Interest Update

Phreesia, Inc. (NYSE:PHR) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 4,404,667 shares, an increase of 21.0% from the February 26th total of 3,639,021 shares. Approximately 7.7% of the company’s shares are sold short. Based on an average trading volume of 1,474,342 shares, the short-interest ratio is presently 3.0 days.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,585 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the transaction, the general counsel directly owned 174,762 shares in the company, valued at approximately $2,972,701.62. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the sale, the insider directly owned 231,723 shares in the company, valued at $3,941,608.23. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 70,358 shares of company stock valued at $1,123,569 in the last 90 days. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC boosted its holdings in shares of Phreesia by 96.2% during the 4th quarter. Hsbc Holdings PLC now owns 46,558 shares of the company’s stock valued at $786,000 after acquiring an additional 22,829 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Phreesia by 354.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock worth $47,000 after purchasing an additional 2,149 shares during the last quarter. Alpine Global Management LLC bought a new stake in Phreesia in the 4th quarter worth approximately $179,000. Invesco Ltd. grew its position in Phreesia by 13.1% in the 4th quarter. Invesco Ltd. now owns 82,176 shares of the company’s stock worth $1,390,000 after purchasing an additional 9,514 shares during the period. Finally, State of Tennessee Department of Treasury purchased a new stake in Phreesia during the 4th quarter valued at $202,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Stock Down 27.0%

NYSE PHR traded down $3.08 during mid-day trading on Tuesday, reaching $8.33. The stock had a trading volume of 16,309,358 shares, compared to its average volume of 1,884,811. Phreesia has a 1 year low of $7.77 and a 1 year high of $32.76. The stock has a market cap of $502.28 million, a PE ratio of -83.30 and a beta of 0.67. The company has a fifty day moving average price of $12.51 and a 200 day moving average price of $17.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). The business had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.11) earnings per share. On average, research analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group lowered their target price on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday. Needham & Company LLC reduced their price objective on Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Robert W. Baird reissued a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday. Finally, Citigroup reissued a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research note on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.00.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.